![Structure and hydrophobic/hydrophilic profile of the most common bile acids.\
Cholic acid (CA) and chenodeoxycholic acid (CDCA) are primary BAs. Deoxycholic acid (DCA) and lithocholic acid (LCA) are secondary BAs. Ursodeoxycholic acid (UDCA) is a primary BA predominantly produced in bears. Hydroxyl groups that are in α-orientation are located below the steroid nucleus and are axial to the plane of the steroid nucleus. Hydroxyl groups that are in β-orientation are located above the steroid nucleus and are equatorial to the plane of the steroid nucleus. The hydrophobicity increases as follows: UDCA, CA, CDCA, DCA, LCA.](nrs08005.f1){#fig1}

![Structure and transcripts of the mouse FXRα gene.\
A) Similar to the human FXRα gene (mapped to chromosome 12 (q23.1)), the mouse FXRα gene (mapped to chromosome 10 (c2)) is characterized by 11 exons and two distinct promoters that initiate transcription from either exon 1 or exon 3. Four distinct transcripts, FXRα1, FXRα2, FXRα3, FXRα4 are generated from the same gene, as a consequence of the alternative splicing of exon 5 and the use of two distinct promoters. ATG indicate the translational starting sites. In blue is indicated the alternative splicing of the 12 bp of exon 5 that encode the MYTG motif in the hinge region. The four FXRα transcripts are shown with the different classical NR receptor domains color coded. B) Upon ligand binding, FXRα binds to FXR response elements (FXRE) of its target genes as a heterodimer with RXR. Examples of consensus sequences are shown.](nrs08005.f2){#fig2}

![FXR ligands.\
Examples of FXR semisynthetic (6α-ECDCA), synthetic (GW4064, Fexeramine, AGN-29, AGN-31, AGN-34) and natural (Z-4,17(20)-pregnadiene-3,16-dione and E-4,17(20)-pregnadiene-3,16-dione) ligands.](nrs08005.f3){#fig3}

![FXR regulates BA metabolism.\
BAs that recirculate in the enterohepatic system activate hepatic and intestinal FXR to regulate genes important for BA metabolism. Hepatic FXR 1) represses BA synthesis by reducing CYP7A1 and CYP8B1 expression *via* SHP and 2) efficiently promotes BA conjugation (conj-BAs) with taurine or glycine *via* BACS and BAAT. FXR controls BA secretion in the small intestine by upregulating the expression of ABC transporters such as MRP2, BSEP and MDR3/Mdr2. When reaching the distal ileum, unconjugated BAs are passively reabsorbed, while conj-BAs are taken up by ASBT at the luminal membrane, shuttled to the basolateral membrane of the ileal enterocyte by the cytosolic transporter IBABP, then secreted in the portal blood *via* the OSTα/β transporter to travel back to the liver and be taken up by the NTCP transporter (repressed by FXR) and complete the enterohepatic circulation. In addition to regulating genes involved in active BA reabsorption in the distal ileum, activation of FXR by BAs also induces FGF19/15, a hormone that is secreted in the portal circulation and that signals to the liver through FGFR4 to repress CYP7A1. During cholestasis, when BAs reach high levels in the liver, FXR also induces OSTα/β to allow BAs to spill over from the liver in the systemic circulation for their final elimination with urine. Under these pathological conditions FXR also induces phase I (CYP3A4/Cyp3a11) and phase II (SULT2A1 and UGTB4) reactions to turn BAs into more hydrophilic and less toxic molecules that are efficiently excreted.](nrs08005.f4){#fig4}

![FXR regulates lipid metabolism.\
By repressing CYP7A1 and CYP8B1 *via* SHP and FGF19, FXR activation may result in hepatic cholesterol accumulation. In the liver, FXR activation results in increased expression of PLPT for the transfer of phospholipids and cholesterol from LDL to HDL, SRB1 for the hepatic uptake of HDL and lipoproteins ApoE, ApoC-I and ApoC-IV. Activation of FXR also leads to the repression of hepatic lipogenesis by reducing the expression of SREBP1-c in a SHP-dependent manner. SREBP1-c induces the expression of key genes for fatty acids synthesis and lipogenesis such as AceCS, FAS, ACC, and GPAT. By increasing the expression of PPARα, FXR also promotes FFA catabolism *via* β-oxidation. By repressing the expression of MTP, an enzyme that controls VLDL assembly, FXR reduces VLDL production. Activation of FXR increases TG clearance by promoting PLP activity, *via* induction of ApoC-II, and by upregulating the expression of VLDL-R and syndecan-1 for the hepatic uptake of LDL and IDL (remnants). Activation of FXR also reduces TG clearance by decreasing the expression of ApoC-III and ANGPTL3, two PLP inhibitors.](nrs08005.f5){#fig5}

![FXR regulates glucose metabolism.\
Activation of hepatic FXR can increase insulin sensitivity not only in the liver, but also in peripheral tissues (skeletal muscle and adipose tissue) by reducing the levels of TGs and FFA. High levels of circulating TGs and FFA can impair insulin signaling and reduce pancreatic insulin secretion, a phenomenon known as "lipotoxicity". The increased insulin sensitivity due to the attenuation of the "lipotoxicity" phenomenon following FXR activation, results in increased glycogen synthesis and reduced gluconeogenesis, two desirable events for the management of diabetes. Activation of FXR induces GSKα expression to promote glycogen synthesis and repress in a SHP-dependent way three key enzymes involved in gluconeogenesis such as PEPCK, FBP1 and G6Pase, but an induction of PEPCK after FXR agonist treatment has been also reported. In this scenario of glucose metabolism regulated by FXR, glucose and insulin increase the expression of FXR.](nrs08005.f6){#fig6}

###### FXR target genes.

List of genes that are transcriptionally-regulated by FXR, with their tissue distribution and function.
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Introduction
============

Nuclear receptors (NRs) are ligand-activated transcription factors that, in response to lipophilic hormones, vitamins, and dietary lipids, regulate many aspects of mammalian physiology, including development, reproduction and metabolism \[[@r29]; [@r106]\].

In 1995, using a two-hybrid yeast system, Seol *et al.* identified several mouse liver cDNA sequences encoding for proteins able to interact with the ligand binding domain (LBD) of the human nuclear receptor RXRα \[[@r167]\]. Among these proteins, a novel protein termed RIP14 (RXR-interacting protein 14) turned out to be unique in its interaction with RXRα. By northern blot analysis, RIP14 expression was detected in kidney and liver, and two isoforms of RIP14 proteins were discriminated. RIP14-1 had a 4-amino acid (MYTG) central insertion, while RIP14-2 presented a 38-amino acid NH~2~-terminal extension. RIP14 was able to bind as a heterodimer with RXRα to previously identified hormone responsive elements (HREs), such as the retinoic acid response element (RARE) from the promoter of the RARβ2 isoform and the ecdysome response element (EcRE) from the *Drosophila* hsp27 promoter. The RIP14-RXRα heterodimer was shown to bind to direct repeats with a 5-, 4- and 2-bp spacer (DR5, DR4 and DR2, respectively) and inverted repeats IR0 and IR1, but not to DR0, DR1, DR3, IR2 and IR5. Importantly, the fact that, in reporter assays, RIP14 was unable to transactivate a reporter containing multiple copies of the βRARE, suggested that RIP14 activity was ligand-dependent. However, the natural ligand for RIP14 was unknown at that time. Later, in 1995, Forman *et al.* were able to clone from a rat liver cDNA library the rat homolog of the mouse RIP14 and they showed that farnesol, an intermediate of the mevalonate pathway, was able to activate rat RIP14 at the concentration of 50 µM \[[@r49]\]. For this reason, rat RIP14 was renamed farnesoid X receptor (FXR) and its expression was detected in the liver, kidney, intestine and adrenal cortex. However, supra-physiological concentrations of farnesol were required to induce FXR activity.

In 1999, FXR was "de-orphanized" when it was demonstrated that primary bile acids (BAs) were the endogenous ligands for FXR \[[@r104]; [@r136]; [@r195]\]. Indeed, FXR was also named BAR (bile acid receptor). BAs were shown to activate FXR at physiological concentrations using an *in vitro* coactivator recruitment assay. BAs are steroid-end products of cholesterol catabolism and are classified as either primary BAs (chenodeoxycholic acid (CDCA) and cholic acid (CA)), synthesized from cholesterol in the liver, or secondary BAs (deoxycholic acid (DCA) and lithocholic acid (LCA)), produced by intestinal bacteria from primary BAs. The majority of circulating BAs are conjugated with glycine or taurine, by a process occurring in the liver (for details about BA homeostasis, see below). The chemical structure of BAs is shown in [Figure 1](#fig1){ref-type="fig"}.

The generation of FXR knock-out mice revealed a clear role for FXR *in vivo* as the master regulator of BA homeostasis \[[@r79]; [@r172]\]. The generation of FXR knock-out mice was a breakthrough for understanding the role of FXR in many BA-related physiological and pathophysiological conditions. Loss of FXR resulted in an enlarged BA pool size as a consequence of increased expression of CYP7A1, the rate-limiting enzyme for the conversion of cholesterol to BAs. Interestingly, FXR knock-out mice also exhibited elevated levels of cholesterol and triglycerides in both plasma and liver. These observations suggested a key role for FXR also in lipid metabolism. Indeed, it was shown in 2004 that FXR activation is required to reduce sterol-regulatory-element-binding-protein-1c (SREBP1-c) expression, a key molecule involved in lipogenesis \[[@r197]\]. In the same year, it was shown that the loss of FXR in mice predisposes to gallstone disease, while its activation may ameliorate this condition by restoring the right biliary BA:cholesterol ratio \[[@r121]\]. Before these findings, the use of FXR as a target for the management of cholestasis was also proposed \[[@r95]\].

In addition to BA and lipid metabolism, it has been shown that FXR also plays an important role in glucose homeostasis by improving insulin sensitivity and glucose tolerance in diabetic mice \[[@r101]; [@r208]\]. Furthermore, in the intestine, FXR is required to protect the epithelium by preventing bacterial overgrowth and consequent mucosa deterioration and bacterial translocation \[[@r70]\]. Finally, FXR also plays a role in liver regeneration \[[@r67]\], and both hepatic \[[@r75]; [@r201]\] and intestinal tumorigenesis \[[@r107]; [@r118]\].

By regulating BAs, lipid and glucose homeostasis, FXR affects many aspects of our metabolism. This makes FXR an attractive pharmacological target for the management of diseases ranging from hyperlipidemia to diabetes, from cholestasis to enterohepatic tumors.

FXR gene and protein structure
==============================

Two *FXR* genes are known and are referred to as *FXRα (NR1H4)* and *FXRβ (NR1H5)*. *FXRβ* is a pseudogene in humans, while it is expressed in rodents, rabbits and dogs. It has been proposed to be a lanosterol sensor, although its physiological function remains to be established \[[@r135]\]. The *FXRα* gene is conserved from fish (teleost fish, *Fugu rubriens*) to humans, which suggests a crucial role for this gene in many species \[[@r103]\]. In humans and mice, *FXRα* is highly expressed in the liver, intestine, kidney and adrenal gland, while low expression has been detected in the heart and adipose tissue \[[@r207]\]. The *FXRα* gene is mapped to human chromosome 12q23.1 and mouse chromosome 10c.2, and it is composed of 11 exons and 10 introns ([Figure 2](#fig2){ref-type="fig"}). As a single gene, *FXRα* encodes four transcript isoforms in both humans and mice, FXRα1 (RIP14-2), FXRα2, FXRα3, and FXRα4 (RIP14-1), as a result of alternative splicing of exon 5 and the use of two distinct promoters that initiate transcription from either exon 1 (5\' promoter) or exon 3 (3\' promoter) \[[@r68]; [@r207]\]. The 5\' or 3\' promoters of the *FXRα* gene regulate the expression of FXRα1 and FXRα2 or FXRα3 and FXRα4 transcripts, respectively. Unlike FXRα2 and FXRα4, FXRα1 and FXRα3 transcripts contain four amino acids (MYTG) immediately adjacent to the DNA-binding domain (DBD) in a region referred to as the hinge domain. Notably, the four FXRα isoforms are expressed in a tissue-specific manner and few FXRα target genes are regulated in an isoform-dependent manner \[[@r85]; [@r86]; [@r207]\]. FXRα1 and FXRα2 are moderately expressed in the adrenal gland and ileum, while FXRα3 and FXRα4 are highly expressed in the ileum, moderately in the kidney and at low levels in the duodenum and jejunum. Some genes such as the ileal bile acid binding protein (IBABP) and fibroblast growth factor 19 (FGF19) are more responsive to the FXRα2 and FXRα4 isoforms (lacking the MYTG motif) than FXRα1 and FXRα3 isoforms \[[@r207]\].

As members of the NR superfamily, the four FXRα proteins (grouped hereafter with the term of FXR) encoded by the single *FXRα* gene (referred to hereafter as *FXR*) present a typical NR structure organized in a highly conserved DBD, a poorly conserved N-terminal domain and a moderately conserved C-terminal LBD ([Figure 2](#fig2){ref-type="fig"}). In the absence of BAs, FXR sits on the HRE of its target genes as a heterodimer with the obligate partner RXR, in association with corepressor proteins. Located in the DBD, two cysteine-coordinated Zn^2+^ finger motifs are responsible for DNA binding and dimerization. The FXR/RXR heterodimer mainly binds IR1 (two canonical AGGTCA inverted repeats with one space nucleotide) and can be activated by either FXR- or RXR-specific ligands. Besides IR-1, other HREs for FXR are direct repeated such as DR-1 and everted repeated such as ER-8. Ligand binding induces conformational changes of FXR that determine the release of corepressor proteins such as NCor (nuclear corepressor), and the recruitment of coactivator proteins, such as SRC-1 (steroid receptor coactivator 1), PGC1α (peroxisome-proliferator-receptor (PPAR)-γ coactivator-1α) \[[@r164]; [@r206]\], CARM-1 (coactivator associated arginine (R) methyl transferase-1) \[[@r1]; [@r13]\], PMRT-1 (protein arginine (R) methyl transferase-1) \[[@r159]\], and DRIP-205 (vitamin-D-receptor-interacting protein-205) \[[@r143]\]. In addition to the LBD, the C-terminal region of FXR contains a ligand-dependent transactivation domain, AF2, that along with a ligand-independent transactivation domain, AF1, in the N-terminal region, interacts with coregulatory proteins.

The LBD of FXR contains a hydrophobic pocket that accommodates lipophilic molecules such as BAs. Crystal structures of the human and rat FXR LBD in complex with two CDCA derivatives ((3-deoxy-CDCA and 6α-ethyl-chenodeoxycholic acid (6α-ECDCA)), the synthetic ligand fexaramine and a coactivator peptide have been solved \[[@r43]; [@r115]\], showing that the amino acids involved in the ligand binding are conserved between human and rat. Moreover, these studies revealed that, beside the classical features of the LBD of NRs, such as its general organization in a 12-α helix bundle, the LBD of FXR presents peculiar characteristics. Similar to other NRs, the LBD of FXR acts as a molecular switch after ligand binding, undergoing conformational changes that result in the recruitment of coactivator proteins by forming a "charge clamp" and a hydrophobic groove that interacts with the LXXLL motifs of the coactivators \[[@r43]; [@r115]\]. Unlike steroid NRs, the LBD of FXR accommodates the steroid nucleus of its ligands in a reverse orientation. Moreover, a second docking site for the LXXLL motifs has been found in the LBD of FXR \[[@r115]\]. Consequently, a coactivator with a single LXXLL motif binds to the FXR LBD with low affinity, while coactivators with two or more LXXLL motifs exhibit higher affinity. The FXR LBD binds the two LXXLL motifs in an anti-parallel manner with one motif located in the classical groove and blocked by a "charge clamp", and the other motif located in the helix 3, without being secured by a "charge clamp". It has been suggested that the FXR LBD uses both LXXLL surfaces to interact with a single coactivator protein, with one of them increasing its affinity for the coactivator. However, this is a hypothesis that needs to be confirmed.

Genetic variability of FXR
==========================

The paucity of nonsynonymous single nucleotide polymorphisms (SNPs) in FXR indicates that this is an important and evolutionarily conserved gene. Two nonsynonymous SNPs have been detected in exon 6 at the level of the hinge region (C643T and G646T). In Chinese- and Hispanic-Americans, two synonymous polymorphisms have been also detected in exon 7 (C783T) and 11 (C1341T), although with very low genotypic frequency. Conversely, a G-1T polymorphism located in the Kozak consensus motif of the exon 3 sequence flanking the start codon is relatively common among European-, Chinese-, African- and Hispanic-Americans \[[@r111]\].

Although this SNP results in reduced transactivation activity, it is not clear whether this effect is due to decreased transcription/translation or the formation of a low-activity, translational variant. Consistent with the *in vitro* studies, reduced hepatic expression of the FXR target gene small heterodimer partner (SHP) was observed \[[@r111]\]. While it remains unclear how the decreased expression of SHP in subjects with G-1T polymorphism would manifest, studies in SHP knock-out mice showed that the lack of SHP leads to increased hepatic insulin sensitivity \[[@r7]\]. Moreover, Japanese patients with mutations in the SHP gene present hypertriglyceridemia and mild obesity \[[@r130]\].

It is worth noting that the expression of another FXR target gene, the ATP-binding cassette (ABC) transporter bile salt export pump (BSEP/*ABCB11*) was not changed. Thus, if there is an effect of FXR polymorphisms, this seems to be target gene-dependent.

It has been suggested that mutations in the FXR gene may also predispose subjects to intrahepatic cholestasis of pregnancy (ICP). Four heterozygous variants have been identified in patients with ICP \[[@r192]\], with three of them showing a functional defect in translational efficiency or activity. Moreover, an FXR haplotype (NR1H4_1) in the Mexican population has been associated with gallstone disease \[[@r80]\]. Taken together, the few data available on FXR polymorphism indicate that this is an important and evolutionarily-conserved gene with rare relevant mutations.

Natural and synthetic FXR ligands
=================================

Naturally-occurring BAs differ in minor structural modifications. Nevertheless, these differences have impact on the affinity for FXR and ability to activate it. Taking advantage of the knowledge of the structure-activity relationship of BAs for the FXR LBD, semisynthetic and synthetic molecules have been made to obtain more selective and potent FXR activators than BAs. Examples of semisynthetic, synthetic and natural ligands are reported in [Figure 3](#fig3){ref-type="fig"}.

Bile acids and semisynthetic bile acid derivatives
--------------------------------------------------

The chemical structure of BAs consists of a steroid nucleus with an acidic side chain ([Figure 1](#fig1){ref-type="fig"}). They are amphipatic molecules with a unique shape characterized by a concave hydrophilic face (α face) and a convex hydrophobic face (β face). The hydrophobic pocket of the FXR LBD interacts with BAs mainly through the β face. The α face contains several hydroxyl groups in the 3, 7 and/or 12α positions that impacts on the ability to activate FXR \[[@r50]\]. Optimal FXR activation through ligand binding requires the proper positioning of helix 3 versus helix 12 in order to generate the LXXLL docking groove. The 7α-hydroxy group confers high capacity to CDCA and synthetic ligands, such as fexaramine and 6α-ECDCA (see below), to activate FXR by inducing a highly stable interaction between helix 3 and helix 12, resulting in a strong agonist activity. Conversely, the absence of a 7α-hydroxy group, in the case of DCA and LCA, compromises stable coactivator recruitment and results in partial agonistic properties. Finally, the FXR LBD cannot accommodate a 12α-hydroxy group and consequently, CA and DCA have low affinity for FXR. The hydrophobic pocket of the LBD contains a series of hydrophobic cavities that can be exploited to first generate further contacts, and then to increase the affinity of the ligand for the FXR LBD. Thus, 6α-ECDCA has a higher affinity than CDCA for FXR. Notably, the carboxyl extremity of BAs is oriented towards the entry of the hydrophobic pocket of the LBD, indicating why conjugated BAs conserve a high affinity for FXR and the ability to activate it \[[@r141]\]. Structural modifications of the carboxyl terminus of BAs may result in altered FXR activity.

The agonist or antagonist properties of a NR ligand are generally evaluated by the recruitment to the LBD of an SRC-1 derivate peptide containing the typical LXXLL motif in a cell-free fluorescence energy transfer (FRET) assay. In this way, it was shown that CDCA and its glycol- and tauro-conjugates were able to recruit a peptide from the SRC-1 coactivator (EC~50~=3.5 µM) to the FXR LBD \[[@r104]; [@r136]; [@r140]; [@r202]\]. On the contrary, DCA, LCA, CA and their conjugates were not able to induce significant coactivator recruitment up to the concentration of 1000 µM (100 µM for DCA), but importantly, they interfered in a dose-dependent fashion with the ability of CDCA to induce FXR-SRC-1 interaction \[[@r92]; [@r104]; [@r136]; [@r202]\]. These data indicate that DCA, LCA, CA and their conjugates act as partial antagonists in this assay. Next, LCA was proposed as an FXR antagonist with partial agonist activity because of its ability to antagonize the CDCA promoting association between FXR and SRC-1 in the cell-free assay, which correlated with antagonist activity on FXR transactivation and the partial induction of BSEP \[[@r202]\]. Finally, ursodeoxycholic acid (UDCA), a hydrophilic BA found in large quantities in bear, was shown to act as a very weak FXR agonist for the induction of BSEP expression and reduction of CYP7A1 expression \[[@r92]\].

In addition to cell-free assays, cell-based assays were carried out to evaluate the ability of different BAs to activate FXR. Initial transfection studies were consistent in indicating CDCA as the most potent FXR activator (EC~50~=50 µM), while DCA and LCA activated FXR with a lower efficacy than CDCA \[[@r104]\]. Hydrophilic unconjugated BAs, such as CA and UDCA, could not activate FXR, and moreover, UDCA turned out to be a partial antagonist, able to inhibit activation by CDCA \[[@r25]\]. Interestingly, in the same transfection assays, the glycol- and tauro-CDCA, -DCA and -LCA were likewise unable to activate FXR. After cotransfection of the apical sodium-dependent BA transporter (ASBT, (*SLC10A2*)), an apical protein required for the active uptake of conjugated BAs, the ability of glycol- and tauro-CDCA, -DCA and -LCA were likewise unable to activate FXR. After ASBT cotransfection, CA and its conjugates were also able to cross the cell membrane and activate FXR \[[@r195]\].

It is worth noting that apart from the cotransfection assays where ASBT was present and a rat form of FXR was used \[[@r195]\], there is no convincing evidence showing that CA is a direct ligand of FXR. However, the FXR LBD is not perfectly conserved between species. This makes, for instance, the mouse FXR LBD much more responsive to CA than its human counterpart \[[@r35]\]. In line with CA being of more physiological importance in mice, they do not have CDCA, the most potent natural activator of human FXR, which is converted to β-MCA.

Taken together, the cell-free and cell-based assays indicate weak correlation between the affinity of BAs for FXR, their ability to induce FXR LBD coactivator interaction and their biological activity. Thus, cell-free assays for coactivator recruitment analysis are not predictive of the transcriptional outcome or the transcriptional outcome depends on many parameters, such as DNA binding sequences and dimerization partners, as suggested for FXR \[[@r92]\] and other NRs \[[@r119]\]. It is also possible that the SRC-1 coactivator assay is not the best investigative model.

Chemical manipulations of the side chain and the steroid nucleus of BAs have been exploited to generate semisynthetic BA derivatives that could be more potent FXR activators. The use of these semisynthetic molecules in transcriptional and ligand-binding assays has generated important information regarding the structure-activity relationship, confirming to some extent the crystallographic studies on the structure of the FXR LBD. The conversion of the 24-carboxyl group of CDCA and CA to the corresponding alcohol, generated compounds with FXR ligand-like activities, similar to CDCA \[[@r50]\]. It is worth noting that while CA can activate FXR only if the ASBT protein is expressed, the corresponding alcohol derivative can activate FXR in the absence of ASBT, indicating that the conversion of the 24-carboxyl group into the corresponding alcohol increases its transport across the cell membrane by passive diffusion.

With respect to the steroid nucleus of BAs, the importance of the C~3~ and C~12~ hydroxyl groups was also addressed \[[@r50]\]. The corresponding 3β and 12β epimers of DCA and LCA were shown to be completely inactive in transactivation assays. Similarly, the introduction of a hydrophobic alkyl group at the 3β and 12β position made the BA derivatives inactive. It is noteworthy that 3β,7α-dihydroxy-3α-methyl-5β-cholan-24-oic acid was able to activate FXR as well as CDCA, indicating that the 2α hydroxyl group of CDCA is not involved in FXR activation.

The ability to activate FXR by early intermediates produced in the BA biosynthetic pathway was also evaluated \[[@r131]\]. The molecules maintaining an intact cholesterol side chain were inactive, while cholestanoic acids, as well as 25- and 26-hydroxylated bile alcohols, were able to activate FXR to the same extent as CDCA. Since these intermediates in the BA biosynthetic pathway are evolutionary precursors of BAs in mammals, it may be that the affinity for them to FXR has been conserved during evolution.

In a small library of BA derivatives, obtained by modification of the ring B to improve the chemical properties/activity relationship, the 6α-methyl derivate of CDCA was identified \[[@r140]\]. With respect to CDCA, this compound exhibited a tenfold higher activity as an FXR agonist. This finding indicated the presence of a hydrophobic pocket in the LBD of FXR corresponding to the 6α position of BAs. In line with this hypothesis, 6α-alkyl derivates such as 6α-ethyl, n-propyl and n-butyl derivatives were generated. Among these compounds, 6α-ECDCA (INT-747) was the most potent FXR activator in a FRET assay. Its activity in this transcriptional assay was three times higher than CDCA with EC~50~=99 nM \[[@r140]\]. Other modifications in the ring B or in the acidic side chain of BAs generated an array of interesting derivatives for the modulation of FXR activity, but none was superior to 6α-ECDCA \[[@r139]\].

Natural extracts
----------------

Guggulipid, the extract from the gum resin of *Commiphora mukul*, is known from traditional Indian medicine for its hypolipidemic properties consisting of reduced serum levels of cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides (TGs). The active principle of guggulipid responsible for these metabolic effects is the guggulsterone, a mixture of Z- and E-4, 17(20)-pregnadiene-3, 16-dione. From the studies on guggulsterone, it is now clear that its metabolic effects are mediated by an array of NRs \[[@r191]\]. Thus, both Z- and E-guggulsterone interact with members of the endocrine NR subfamily, including glucocorticoid receptor (GR), mineralocorticoid receptor (MR), androgen receptor (AR), progesterone receptor (PR) and estrogen receptor α (ERα) \[[@r24]\], as well as members of the adopted orphan NR subfamily, such as pregnane X receptor (PXR) \[[@r22]\] and FXR. Regarding FXR \[[@r36]; [@r190]; [@r199]\], it has been shown by transfection experiments that both Z- and E-guggulsterone are unable to activate this NR, while they can interfere with CDCA activity. These antagonistic properties were confirmed in a cell-free coactivator binding assay, where guggulsterone fails to recruit SRC-1 peptide \[[@r190]; [@r199]\]. Nevertheless, guggulsterone was shown to enhance CDCA and GW4064 (a selective and potent synthetic FXR agonist) induced BSEP expression \[[@r36]\]. Thus, despite its lack of selectivity, guggulsterone might represent an example of a gene-selective modulator for FXR.

Other natural extracts contain FXR modulators. Cafestol, a diterpene isolated from unfiltered coffee brew, has been shown to have agonistic effects on FXR and PXR in HepG2 cells, similar to those of CDCA and pregnenolone 16-α carbonitrile (PCN), but it was unable to induce hepatic FXR target genes *in vivo*. \[[@r156]\]. Indeed, the hypercholesterolemic properties of cafestol are due to its ability to induce the fibroblast growth factor 15 (FGF15) in the small intestine, which by repressing CYP7A1, would induce accumulation of cholesterol in the body \[[@r129]\]. Furthermore, stigmasterol, a soy lipid-derived phytosterol, was able to interfere with the induction of FXR target genes in HepG2 cells \[[@r28]\]. Finally, the prenylated chalcone xanthohumol, derived from beer hop, was shown to reduce serum and hepatic TGs levels in animal models of diabetes and to induce BSEP expression in hepatoma cells, suggesting that this molecule may be an FXR agonist \[[@r132]\].

Synthetic ligands
-----------------

Since BAs do not display strong selectivity for FXR, scientists were prompted to develop synthetic molecules with higher affinity and selectivity for this NR. A lead compound in this field is represented by the TTNPB compound, a synthetic retinoid with low affinity for FXR identified in coactivator recruitment assays \[[@r136]; [@r203]\]. Starting from the structure of the TTNPB, different stilbene derivatives were synthesized \[[@r97]; [@r105]\]. Among these, GW9047 exhibits good selectivity, but low affinity for FXR. Modulations of the structure of GW9047 led to GW4064, a selective and potent activator of FXR (EC~50~=90 nM) that is still seen as the reference compound. This synthetic molecule is an FXR agonist active both *in vitro* and *in vivo*, but unfortunately it displays a limited bioavailability that precludes the possibility of using it in clinical phases. Starting again from TTNBP, new modifications on its backbone, to avoid retinoic acid receptor (RAR) binding, yielded other FXR ligands, such as AGN29, AGN31 and AGN34 \[[@r45]\]. While AGN29 and AGN31 exhibit agonistic properties for both FXR and RXR with an EC~50~=1 µM, AGN34 turned out to be an FXR and RXR antagonist. The benzopyran structure was also used as a starting point to generate FXR agonists and the biaryl cinnamate derivates such as fexaramine and fexarine resulted as selective and potent FXR agonists with an EC~50~=38 nM and EC~50~=36 nM, respectively \[[@r43]\]. Interestingly, gene expression analysis on primary human hepatocytes revealed that CDCA, GW4064 and fexaramine activated FXR target genes differently, suggesting that these FXR ligands may also act as gene--selective FXR modulators. This means that they can modulate the expression of various FXR target genes in different manners, either as agonists or antagonists. This phenomenon could be explored to develop FXR modulators in which therapeutic effects may be separated by unwanted side effects. Finally, 1,1-biphosphonate esters were shown to activate FXR with anti-proliferative and hypocholesterolemic effects \[[@r128]\].

FXR as more than a bile acid sensor
===================================

For a long time the physiological effects of BAs were attributed exclusively to their physico-chemical properties, which allow them to form fat-solubilizing micelles for the absorption of lipophilic nutrients. Besides this well-established role in dietary lipid absorption, in the last few years it has been revealed that BAs also behave as signaling molecules (hormones) with systemic endocrine functions. BAs are in fact ligands for both the G-protein-coupled receptor (GPCR) TGR5 \[[@r110]; [@r196]\] and the nuclear receptor FXR \[[@r104]; [@r136]; [@r195]\]. Activation of the BA-TGR5 pathway increases energy expenditure in brown adipose tissue, which would be beneficial against obesity and insulin resistance. Through activation of their sensor FXR, BAs can regulate not only their own homeostasis, but also cholesterol, TG, and glucose metabolism. Thus, the BA-regulated transcriptional pathways *via* TGR5 and FXR are promising, novel drug targets for the management of metabolic diseases such as diabetes, hyperlipidemia, gallstone disease, cholestasis and enterohepatic tumors.

FXR and bile acid metabolism
----------------------------

BAs are amphipathic molecules synthesized in the liver from cholesterol by multiple enzymatic steps occurring in different hepatic cellular compartments, such as the cytosol, mitochondria, endoplasmic reticulum and peroxisomes \[[@r161]\]. This is the so called "classical" pathway. How the nascent BAs can shuttle from one compartment to another is still unknown. Newly-synthesized BAs are termed primary BAs and consist of CDCA and CA. The "classical" pathway in humans leads to an equal amount of CDCA and CA. An "alternative" pathway is responsible for the production of oxidized cholesterol molecules that are afterwards converted predominantly to CDCA in the liver \[[@r30]\]. Before active secretion of BAs into the canalicular lumen, primary BAs are conjugated at the C~24~ carboxyl group with the amino acids taurine or glycine \[[@r46]\] ([Figure 1](#fig1){ref-type="fig"}). This amidation process is very efficient and it is important to make BAs less hydrophobic, less cytotoxic, and more readily secretable into bile \[[@r194]\]. Thus, the majority of BAs present in bile are conjugated.

After a postprandial stimulus, BAs are released from the gall bladder into the duodenum to promote the absorption of dietary lipids and lipid soluble vitamins. Then, BAs travel along the intestine and at the distal ileum the majority of the BAs (95%) are actively absorbed and returned to the liver *via* the portal vein, to be re-secreted into the bile \[[@r98]\]. This process of BA recycling is called enterohepatic circulation and is of extreme importance in terms of energy saving, since BA biosynthesis is an energetically expensive process involving more than 15 enzymes \[[@r98]\]. Only 0.5 g of BAs per day is lost through feces. This loss is compensated by *de novo* hepatic synthesis.

During the enterohepatic circulation, conjugated BAs undergo a de-conjugation process in the distal intestine by bacterial enzymes. The de-conjugated BAs are then passively absorbed by enterocytes and returned to the liver where they will be re-conjugated. Primary BAs (CDCA and CA) are transformed from anaerobic bacteria present in the colon to secondary BAs (LCA and DCA, respectively). Also secondary BAs are passively re-absorbed from enterocytes to travel back to the liver where they will be conjugated. Thus, the total BA pool is represented by secondary and, for the majority, primary BAs. LCA, after uptake from the liver, undergoes a double conjugation, with glycine or taurine first, and then with a sulfonyl group. In this way, LCA is not efficiently absorbed in the distal ileum and thereby eliminated with the feces. This is beneficial since LCA is highly cytotoxic.

BAs are able to repress their own synthesis in a feed-back way through a synergistic mechanism that involves FXR in the liver and in the intestine. Under fasting conditions, BAs are synthesized from cholesterol in the liver and stored in the gall bladder, ready to be delivered in the small intestine after a postprandial stimulus. The rate-limiting step enzyme in the biosynthetic pathway for the conversion of cholesterol to BAs is the CYP7A1 enzyme, a member of the cytochrome P450 (CYP) superfamily \[[@r161]\]. The orphan nuclear receptor liver receptor homolog-1 (LRH-1) and liver X receptor (LXR), an oxysterol sensor, are two important inducers of CYP7A1 mRNA levels in rodents \[[@r54]; [@r88]; [@r90]; [@r138]\]. In human, on the other hand, LXR represses CYP7A1 \[[@r55]\]. The inhibition of CYP7A1 by LXR in human may represent a physiological strategy to suppress the absorption of dietary cholesterol in the intestine. BAs are in fact essential for the intestinal absorption of cholesterol. In line with this hypothesis, a high-cholesterol diet reduced the expression of CYP7A1 in the liver of African Green monkeys, a species that is similar to humans in cholesterol and lipoprotein metabolism \[[@r160]\]. Thus, while rodents would deal with excessive cholesterol by stimulating CYP7A1 expression in order to increase the catabolism of cholesterol into BAs, humans may have evolved an alternative strategy, whereby the absorption of cholesterol in the intestine is blunted through a decrease in the BA pool as a result of CYP7A1 repression by LXR.

After feeding, BAs are delivered from the gall bladder in the duodenum, in order to travel through the enterohepatic circulation. Activation of FXR in the liver induces the expression of SHP, which interacts with LRH-1 and represses its activity \[[@r54]; [@r88]; [@r99]\]. As a consequence, SHP-LRH-1 interaction results in reduced expression of CYP7A1 and ultimately BAs synthesis. However, the fact that BAs are still able to repress CYP7A1 in SHP knock-out mice indicates that other mechanisms for the repression of this enzyme are present. Indeed, FXR, in the murine distal ileum, induces FGF15 (FGF19 is the human ortholog), a hormone secreted in the portal circulation that reaches the liver to bind to the fibroblast growth factor receptor 4 (FGFR4) and repress CYP7A1 *via* a c-jun N-terminal kinase-dependent pathway \[[@r69]\]. This mechanism constitutes a crosstalk between the intestine and liver for the regulation of BA synthesis. The use of tissue-specific FXR knock-out mice for the liver and intestine assessed the relative contribution of hepatic and intestinal FXR in the repression of CYP7A1 and revealed a more determinant role for the intestinal FXR \[[@r74]\].

In addition to CYP7A1, another critical cytochrome, CYP8B1, is involved in the classical pathway of BA synthesis. This enzyme controls the CA:CDCA ratio by regulating the synthesis of CA. Just like CYP7A1, CYP8B1 is repressed by FXR *via* SHP \[[@r204]\], but in this case SHP interacts and represses the ability of the hepatic nuclear factor 4α (HNF-4α) to induce CYP8B1 expression. Moreover, as shown in hepatic specific FXR knock-out mice, CYP8B1 expression was repressed, probably *via* FGF15 \[[@r74]\]. Notably, hepatic specific knock-out mice for LRH-1 exhibit reduced expression of CYP8B1, but not of CYP7A1. These findings suggest that hepatic LRH-1 is involved in the control of the composition of the BA pool, but not of its size, which is instead mainly regulated by the FXR-FGF15 pathway \[[@r89]; [@r112]\].

Newly-synthesized BAs are conjugated with taurine or glycine and then actively secreted in the gall bladder. FXR regulates both of these critical processes. The amidation reaction requires an initial activation of BAs to CoA-thioesters by the BA CoA synthase (BACS). These activated BAs become the substrate for the BA-CoA:amino acid N-acetyltransferase (BAAT) enzyme, which is responsible for the conjugation with glycine or taurine \[[@r173]\]. Conjugated BAs are potent natural activators of FXR \[[@r136]\], which positively regulates the expression of BACS and BAAT \[[@r144]\]. Monoanionic- and dianionic-conjugated BAs are then actively secreted in the gall bladder by BSEP and the multidrug related protein 2 (MRP2/*ABCC2*), respectively. These transporters belong to the ABC transporter family and are both induced by FXR at the transcriptional level. Moreover, FXR activation also induces the expression of the multidrug protein 3/2 (MDR3/Mdr2, *ABCB4/Abcb4*), another ABC transporter involved in the biliary secretion of phosphatidylcholine \[[@r117]\] ([Figure 4](#fig4){ref-type="fig"}). The regulation of these ABC transporters is of critical importance in order to avoid BA accumulation in the liver and consequent hepatic injury. Indeed, mutations in the BSEP and MDR3 proteins are responsible for progressive familial intrahepatic cholestasis (PFIC) type 2 \[[@r179]\] and 3 \[[@r39]\], respectively (see below).

After postprandial stimulus, BAs are secreted from the gall bladder into the small intestine to allow the absorption of lipophilic nutrients. In the distal ileum, conjugated BAs are actively reabsorbed in the portal blood, while unconjugated BAs are only partially absorbed by passive diffusion. At the enterocyte brush border membrane, ASBT determines the uptake of BAs \[[@r37]; [@r133]\]. Once BAs are taken up by ASBT, they are shuttled from the apical to the basolateral membrane by IBABP \[[@r53]; [@r184]; [@r185]\]. Finally, BAs are secreted in the portal blood by the heterodimeric organic solute transporter α/β (OSTα/β \[[@r38]\] ([Figure 4](#fig4){ref-type="fig"}). This complex process of active BA absorption is entirely orchestrated by FXR. Activation of FXR in the distal ileum downregulates the expression of ASBT, while expression of IBABP \[[@r57]; [@r79]\] and OSTα/β is induced\[[@r84]; [@r153]\]. Notably, FXR directly induces *IBABP* and *OSTα/β* expression on the level of their promoters, while the expression of human *ASBT* is negatively regulated *via* SHP \[[@r125]\].

Similar to the intestine, the active transport system for BAs absorption regulated by FXR also exists in the bile duct and kidney. In cholangiocytes, conjugated BAs are absorbed by ASBT at the canalicular membrane and secreted by MRP3 and OSTα/β at the basolateral membrane \[[@r7]\]. Also in the kidney, conjugated BAs are absorbed by ASBT, localized at the apical membrane of proximal renal tubular cells, and then secreted by OSTα/β from the basolateral membrane in the systemic circulation \[[@r7]; [@r31]; [@r33]\]. Indeed, under normal conditions, BAs are not excreted into urine.

Although the adrenal gland cortex is not known to be involved in any aspect of BA metabolism, the expression of FXR has been detected at high levels also in this tissue \[[@r49]\]. Herein, *OSTα* and *OSTβ* were identified as FXR target genes by *in vitro* and *in vivo* approaches \[[@r86]\]. It has been proposed that when the serum levels of BAs increase, such as in cholestasis, OSTα and OSTβ would facilitate the uptake of conjugated BAs into the adrenal glands, resulting in a feed-forward activation of OSTα and OSTβ by FXR. Since OSTα and OSTβ form a multifunctional facilitative transporter, this heterodimer may also export specific substrates from the adrenal glands. In frog oocytes, OSTα and OSTβ have been shown to increase the efflux of dehydroepiandrosterone-3-sulfate \[[@r7]\]. The human adrenal cortex synthesizes and secretes dehydroepiandrosterone-3-sulfate, suggesting that also in humans the OSTα/β heterodimer export conjugated steroid intermediates from the adrenals glands into the blood while exchanging conjugated BAs. It is unknown whether apart from BAs, other endogenous molecules in the adrenal glands could activate FXR. For example, androsterone, a metabolite derived from adrenal steroids, has been reported to activate FXR \[[@r66]\]. However, since this activation is relatively weak, it remains unclear whether androsterone or other steroid intermediates are of physiological importance for FXR activation.

BAs are detergent-like molecules. Thus, despite their beneficial role in solubilizing lipophilic nutrients facilitating their intestinal absorption, accumulation of high levels of BAs, especially secondary BAs, can be detrimental. Notably, BA cytotoxicity increases linearly with the hydrophobic index \[[@r122]\]. Indeed, the order of increasing cytotoxicity is UDCA, CA, CDCA, DCA and LCA ([Figure 1](#fig1){ref-type="fig"}). The cytotoxic effects of BAs have been demonstrated in FXR knock-out mice which spontaneously develop hepatic tumors \[[@r75]; [@r201]\]. Moreover, accumulation of BAs in the liver is believed to play a pivotal role in cholestasis-associated liver damage (see below). Thus, the concentration of BAs needs to be tightly regulated. As a BA sensor, FXR controls not only BAs synthesis, but also their metabolism and clearance. While the first process is evident under physiological conditions during the fast-fed state switch, the ability of FXR to induce BAs biotransformation and elimination is more evident under pathological conditions (e.g., cholestasis).

The biotransformation process of BAs consists of two phases occurring mainly in the liver. Phase I involves oxidation reactions, which generate more polar products. Then, phase II enzymes are responsible for the conjugation of phase I products with endogenous molecules to further increase their water solubility. At this point, conjugated BAs are polar enough to be easily eliminated from the body. However, they cannot exit the liver by passive diffusion. Thus, a phase III of active secretion is required. In this respect, BAs can be secreted into the bile by MDR3/Mdr2 and BSEP or into the systemic circulation by OSTα/β and MRP members for elimination through urine. This latter process occurs when secretion of BAs into bile is somehow impaired, as during cholestasis.

In the liver, CYP3A4/Cyp3a11 is the most important enzyme involved in phase I reactions. It catalyzes hydroxylation of BAs at different positions, leading to 3-oxo-, 1-β-, 6-α-, and 22-hydroxy Bas production \[[@r5]; [@r20]\]. Activation of FXR by GW4064 results in the induction of CYP3A4 in HepG2 cells and Cyp3a11 in wild type mice, but not in FXR knock-out mice \[[@r52]\]. Furthermore, FXR can regulate phase II enzymes involved in glucuronidation and sulfonation reactions. FXR response elements have been found in the promoter of the *SULT2A1* gene \[[@r174]\], whose encoded protein generates 3-α-sulfated BAs. These BAs are low in healthy subjects \[[@r145]\], while high levels are detected in cholestatic patients \[[@r181]\], indicating the protective role of SULT2A1. However, while FXR activation fails to induce *SULT2A1* expression in HepG2 cells \[[@r47]\], the expression of *UGT2B4* for the glucuronidation of 6α-hydroxilated BAs is upregulated \[[@r8]\]. Interestingly, in colon carcinoma CaCO2 cells, FXR acts as negative regulator of the *UGT2B7* gene, whose encoded enzyme is involved in the formation of 3-hydroxy-glucuronidated BAs \[[@r100]\]. Thus, FXR seems to control BA glucuronidation in a tissue- and isoform-specific manner.

Under physiological conditions, bile is the preferential route used by the liver to secrete BAs. However, under cholestatic conditions, BAs are also secreted into the systemic circulation by an alternative basolateral export system, including OSTα/β, MRP3 and MRP4 \[[@r38]\]. Under normal conditions, FXR induces the expression of canalicular BSEP and MRP2, but when BAs accumulate in the liver at toxic levels, FXR also induces the expression of basolateral OSTα/β for the secretion of BAs into the systemic circulation and finally urinary elimination. In the kidney, BAs are normally reabsorbed by the ASBT transporter localized at the apical membrane of proximal renal tubular cells and then secreted by the basolateral membrane OSTα/β into the systemic circulation \[[@r7]; [@r31]; [@r33]\]. Thus, under healthy conditions, BAs are not excreted into urine. Conversely, during cholestasis, passive glomerular filtration of serum BAs and repression of ASBT expression \[[@r87]\] account for the loss of BAs through urine. Since FXR induces the expression of OSTα/β in the kidney \[[@r86]\], the use of a selective antagonist for FXR in the kidney could have a beneficial effect for patients with cholestasis. A list of FXR target genes is reported in [Table 1](#table-fn1){ref-type="table"}.

FXR and cholesterol-triglyceride homeostasis
--------------------------------------------

The downregulation of CYP7A1 *via* FXR signaling leads to decreased cholesterol catabolism with consequent accumulation of hepatic and serum cholesterol. Thus, the use of an FXR antagonist could represent a promising approach to decrease cholesterol levels by enhancing the conversion of cholesterol into BAs. In line with this idea, as mentioned previously, guggulsterone, a plant sterol used in Indian herbal medicine, has been shown to block FXR activity and reduce serum LDL levels, while increasing high-density lipoprotein (HDL) levels \[[@r190]\]. Moreover, adenoviral CYP7A1 over-expression in LDL-receptor knock-out mice, which exhibit high levels of LDL-cholesterol, resulted in reduced LDL-cholesterol levels \[[@r154]\]. Taken together, these data suggest that FXR antagonists may be used for the management of atherosclerosis. However, the other side of the coin is the role that FXR plays in intestinal cholesterol absorption. It has been shown that FXR knock-out mice exhibit increased intestinal absorption of cholesterol, which indicates a negative regulatory role for FXR in intestinal cholesterol absorption \[[@r83]\]. The increase in intestinal cholesterol absorption is probably due to increased solubilization of cholesterol in the gut *via* the increased amount of circulating BAs in these mice. Moreover, FXR activation seems to contribute to reverse cholesterol transport, a process that results in the delivery of cholesterol from peripheral tissues to the liver for biliary disposal and consequent fecal elimination \[[@r83]\]. In this metabolic scenario, FXR regulates the expression of phospholipids transfer protein (PLPT), responsible for the transfer of phospholipids and cholesterol from LDL to HDL, hepatic lipoproteins, such as ApoE, ApoC-I, ApoC-IV, and scavenger receptor B1 (SRB1), which is involved in the hepatic uptake of HDL and is one of the major actors in the clearance of serum HDL cholesterol esters ([Figure 5](#fig5){ref-type="fig"}).

The BA pool size can also affect TG metabolism. Early clinical studies suggested a direct relationship between BA and TG levels, showing that patients with decreased BA synthesis due to CYP7A1 deficiency presented high plasmatic levels of TGs \[[@r151]\]. Moreover, subjects with monogenic familial hypertriglyceridemia displayed defects in ileal BA reabsorption \[[@r2]\]. In line with these evidences, dyslipidemic patients treated with BA-sequestering resins (e.g., cholestyramine or cholestipol) presented increased levels of plasma TG and very-low-density lipoprotein (VLDL) \[[@r2]; [@r14]; [@r34]\]. Conversely, administration of a BA such as CDCA for the management of hypertriglyceridemia and gallstone disease resulted in decreased TG levels \[[@r2]; [@r12]; [@r15]\]. The ability of BAs to act as hypotriglyceridemic agents has also been confirmed in animal models. In this respect, KK-A(y) mice, an animal model of hypertrigliceridemia, exhibit reduced TG serum levels, hepatic TG accumulation and VLDL secretion after treatment with CA \[[@r197]\].

Following the discovery that FXR is a transcriptional mediator of the physiological effects of BA, it was speculated that the activation of FXR by synthetic ligands could be exploited to modulate TG metabolism. Thus, mice and rats treated with GW4064 showed reduced plasma TG levels \[[@r32]; [@r101]; [@r105]; [@r208]\]. Interestingly, administration of GW4064 was also able to improve hypertriglyceridemia in *ob/ob* and *db/db* mice, two animal models of insulin resistance \[[@r27]; [@r208]\]. Moreover, FXR agonists reduced free fatty acids (FFA) levels in insulin-resistant rodents \[[@r18]; [@r208]\]. The important role of FXR in regulating TG homeostasis has been highlighted in FXR knock-out mice which exhibit a lipid profile characterized by high levels of serum TGs and increased hepatic synthesis of VLDL \[[@r172]\].

FXR controls TG metabolism by regulating hepatic *de novo* lipogenesis and triglyceride clearance. Upon activation by BA or synthetic ligands, FXR downregulates the expression of SREBP-1c \[[@r197]\], a transcription factor that plays a critical role in stimulating fatty acid synthesis and lipogenesis by inducing the expression of key enzymes such as the fatty acid synthase (FAS), acetyl-CoA synthase (AceCS), acetyl-CoA (ACC) and glycerol-3-phosphate (GPAT) \[[@r65]\] ([Figure 5](#fig5){ref-type="fig"}). This metabolic scenario has been elucidated in a mouse model of obesity and type 2 diabetes, the KK-A(y) mouse \[[@r197]\]. When fed with a natural (CA) or synthetic (GW4064) ligand for FXR, these mice exhibit a significant reduction in hepatic and serum TG levels, and VLDL secretion as a consequence of the induced expression of SHP *via* FXR. By interfering with LRH1, SHP is able to blunt the ability of LXR to induce SREBP-1c expression. Notably, insulin induces SREBP-1c expression and maturation \[[@r48]; [@r171]\], but also LXR \[[@r178]; [@r183]\]. Thus, while the LXR-LRH1- SREBP-1c cascade plays a key role in inducing lipogenesis, on the other hand the FXR-SHP-SREBP-1c cascade plays a crucial role in repressing lipogenesis. The central role of SHP in inhibiting SREBP-1c was confirmed by the combined use of natural (CA) or synthetic (GW4064) FXR agonists and SHP knock-out mice \[[@r197]\]. In these mice, activation of FXR did not result in lower TG levels. Interestingly, the observation that FXR knock-out mice have normal or even reduced SREBP-1c mRNA levels \[[@r44]; [@r206]\] suggests that FXR-independent mechanisms also must play an important role. However, since FXR knock-out mice exhibit increased serum and hepatic TG levels along with increased production of VLDL, FXR activation may control *de novo* lipogenesis *via* SREBP-1c-dependent and -independent mechanisms.

In addition to the reduction of *de novo* lipogenesis, FXR activation may also modulate TG clearance. This additional TG-lowering effect of FXR is explained at the molecular level by the induction of key genes, such as Apo-C-II \[[@r72]\], an activator of lipoprotein lipase (LPL) activity responsible for VLDL-TG hydrolysis, and the VLDL receptor, in both human and mouse livers, which enhances the clearance of TG-rich lipoproteins ([Figure 5](#fig5){ref-type="fig"}). Activation of FXR has also been shown to induce the *in vitro* expression of syndecan-1 \[[@r4]\], a transmembrane herpain sulfate proteoglycan responsible for the clearance of remnant particles. Also, activation of FXR represses the expression of Apo-C-III \[[@r32]\] and ANGPTL3 \[[@r197]\], two PLP inhibitors. Finally, an FXR agonist may induce the expression of peroxisome proliferator activated receptor α (PPARα) and in turn its target gene pyruvate dehydrogenase kinase-4 (PDK-4), to promote fatty acid oxidation \[[@r142]; [@r163]\] ([Figure 5](#fig5){ref-type="fig"}). Taken together, these studies propose FXR as a pharmacological target for the management of hypertriglyceridemia and fatty liver disease, two common features of the metabolic syndrome in humans.

In summary, the use of FXR agonists would be beneficial for the reduction of TG levels, but detrimental in regard to the induction of LDL-cholesterol and reduction of HDL-cholesterol levels. Instead, the use of FXR antagonists would be beneficial to reduce LDL-cholesterol and increase HDL-cholesterol levels, but disadvantageous because of the increased TG levels. Indeed, the benefit of FXR antagonists or agonists in diseases such as atherosclerosis, hypercholesterolemia and hypertriglyceridemia, remains to be established. For the future, the identification of specific FXR isoforms linked to a specific lipid-metabolic pathway would be extremely helpful for the design of specific FXR (ant-)agonists targeting the desired pathway without undesirable side effects.

FXR and glucose metabolism
--------------------------

A physiological role for FXR in glucose metabolism has emerged in the last few years by the discoveries of the effects of FXR on gluconeogenesis, glycogen synthesis, and insulin sensitivity. The link between FXR and glucose homeostasis has been highlighted by several studies showing that BAs profile is altered by diabetes \[[@r175]\]. The BA pool size is markedly increased in rat models of diabetes, suggesting that insulin may affect BA synthesis and secretion \[[@r61]; [@r126]\]. Indeed, insulin administration was able to restore a normal BA pool size in experimental models of diabetes \[[@r127]; [@r193]\]. Moreover, liver-specific insulin receptor knock-out mice showed increased bile volume, suggesting a larger BA pool size \[[@r116]\]. Taken together, these observations indicate that the negative feedback mechanism repressing BA synthesis is impaired in diabetes. Concurrently, in rat models of diabetes, hepatic FXR expression is decreased and CYP7A1 consequently induced. Thereby, BA pool size is increased, but notably after insulin administration FXR and CYP7A1 gene expression is restored \[[@r44]\]. Moreover, BA synthesis is reduced *in vitro* in rat hepatocytes treated with a physiological concentration of insulin, due to the reduced expression of CYP7A1 \[[@r187]\].

While insulin regulates FXR expression, FXR has an impact on insulin sensitivity. Compared to wild type mice, FXR knock-out mice exhibit impaired glucose tolerance and insulin sensitivity \[[@r26]; [@r101]; [@r208]\]. Conversely, mice treated with natural (CA) and synthetic (GW4064) FXR ligands, or infected with an adenovirus expressing a constitutively-active form of FXR (VP16-FXR), showed a marked reduction in plasma glucose levels and improved insulin sensitivity \[[@r26]; [@r101]; [@r208]\]. These effects were seen in mouse models of diabetes such as db/db, ob/ob and KK-A(y) mice. Since FXR is not expressed in skeletal muscle and very low levels are detected in white adipose tissue, it is conceivable that the molecular mechanisms behind the peripheral insulin sensitizing effect of FXR could be indirect. FXR knock-out mice exhibit elevated circulating FFA, as well as increased content of TGs and FFA in the skeletal muscle \[[@r26]; [@r101]\]. It is believed that this phenomenon known as "lipotoxicity" could impair insulin signaling at the peripheral level \[[@r162]\] ([Figure 6](#fig6){ref-type="fig"}). Moreover, a similar mechanism could operate in the liver and pancreas, in the latter case reducing the secretion of insulin. Activation of FXR would reduce the "lipotoxicity" phenomenon by decreasing the levels of TGs and FFA (see FXR and TG metabolism) and restoring insulin secretion and sensitivity. Indeed, *in vivo* studies on FXR knock-out mice demonstrate a lipoatrophic phenotype that would be responsible for interfering with insulin sensitivity \[[@r26]; [@r158]\]. Also, it has recently been shown that treatment of adipocyte-like 3T3-L1 cells with FGF19 results in increased glucose uptake \[[@r81]\]. Moreover, resistance to insulin desensitization was observed in FGF19 transgenic mice. However, the FGF19 effects are less important in white adipose tissue than in the liver, suggesting that the extra-hepatic activity of FGF19 was due to supra-physiological concentrations \[[@r186]\]. It is conceivable that an increase in fatty acid oxidation, as a consequence of the inhibition of hepatic acetyl CoA carboxylase 2 (ACC2) and steaoryl- CoA desaturase-1 (SCD-1), would account for the reduced hepatic TG levels and the following improved insulin sensitivity. Overall, these studies suggest that the FXR-dependent insulin-sensitizing effects may, to some extent, be mediated by FGF19. In order to better dissect this scenario, studies of tissue-specific FXR knock-out mice are required to demonstrate the relative contribution of the liver, intestine and white adipose tissue in insulin sensitivity. On the other hand, one cannot exclude that FXR activation also might lead to increased synthesis or secretion of insulin by the pancreatic cells, and the higher circulating insulin levels could somewhat counteract the insulin-resistant phenotype of the diabetic animal models.

Another goal in diabetes management, to improve insulin sensitivity, is to limit hepatic output of glucose by reducing gluconeogenesis and glycogenolysis \[[@r120]\]. In this respect, FXR would be a suitable target since it has been demonstrated that the activation of FXR may reduce hepatic gluconeogenesis and induce glycogen synthesis \[[@r26]; [@r101]; [@r208]\]. Since VP16-FXR over-expression in the liver confirmed the results obtained by pharmacological treatment known to activate FXR in the liver, intestine and kidney, a key role for hepatic FXR in glucose homeostasis, rather than extra-hepatic FXR, is inferred. In the liver of mouse models of diabetes, activation of FXR represses the expression of phosphoenoyl-pyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) and fructose 1,6-bis phosphatase (FBP1), three rate-limiting enzymes in the glucogenetic process \[[@r101]; [@r208]\] ([Figure 6](#fig6){ref-type="fig"}). At the molecular level, these findings are explained by the repressive effects of the FXR-SHP pathway on transcription. The expression of PEPCK, G6Pase and FBP1 is positively-regulated by different transcription factors and coactivators. Specifically, HNF4α, GR, forkhead transcription factor Foxo1 and PGC1α cooperate to induce the expression of these three enzymes in the fasting state. Activation of FXR by CA \[[@r101]\] or GW4064 \[[@r208]\] induces the expression of SHP, which in turn disrupts the interaction of PGC1α with GR, HNF4α and Foxo1 with a final decrease of gluconeogenesis in db/db and KK-A(y) diabetic mouse models, but not in FXR knock-out mice \[[@r21]; [@r200]\]. In support of the concept that BAs repress gluconeogenesis *via* the FXR-SHP pathway, over-expression of SHP reduces gluconeogenic gene expression. Besides the direct role of SHP in reducing the mRNA levels of these three enzymes, it is also possible that FXR may act indirectly by increasing hepatic insulin sensitivity and reducing serum FFA levels. Notably, in contrast with the diabetic mice, studies on wild type mice with FXR agonists showed stimulation \[[@r176]; [@r208]\] or repression \[[@r40]; [@r101]; [@r200]\] of PEPCK, paralleled by decreased or unchanged glucose levels \[[@r101]; [@r176]; [@r208]\]. The explanation for these discrepancies remains to be determined. Moreover, the *in vitro* use of GW4064 resulted in induction rather than suppression of PEPCK \[[@r176]\]. In line with this evidence, administration of GW4064 to fed mice also resulted in the upregulation of PEPCK. These differences in the literature may be due to the fast-feeding regulation of this important FXR-driven scenario. Parallel to G6Pase reduced expression, activation of FXR induces glycogen synthesis in the liver of diabetic db/db mice as a consequence of increased phosphorylation of glycogen synthase kinase 3α (GSK3α), a critical regulator of glycogen synthase \[[@r208]\] ([Figure 6](#fig6){ref-type="fig"}). In accordance with this finding, FXR knock-out mice exhibit reduced hepatic glycogen content \[[@r27]\].

Despite the discrepancies in the literature regarding the role of FXR in glucose metabolism, FXR agonists may be useful for the management of type 2 diabetes. Moreover, the observation that activation of FXR results in insulin substrate receptor 1 (IRS-1) phosphorylation in the liver and adipose tissue suggests a potential application of FXR ligands for the management of patients with insulin resistance \[[@r101]\]. Studies on human patients are ongoing and the results will shed light on FXR as an anti-diabetic target.

A list of FXR target genes involved in glucose metabolism is reported in [Table 1](#table-fn1){ref-type="table"}.

FXR and disease
===============

Cholestasis
-----------

Cholestasis is a pathological condition characterized by impairment or reduction of bile flow. It results from defects in the process of bile formation in hepatocytes or cholangiocytes (intrahepatic cholestasis), or alternatively from physical obstructions in bile ducts due to tumors or stones (extrahepatic cholestasis). As a consequence, accumulation of potentially toxic biliary constituents leads to initial hepatic fibrosis and inflammation that may result in cirrhosis, cancer and finally liver failure. Alterations in the bile formation process can derive from inflammation, drug administration, pregnancy or hereditary defects in the transport systems needed for bile formation/secretion. In the latter case, PFIC1, also termed Byler disease, affects patients with mutations in FIC1, a putative aminophospholipid transferase on the hepatocyte canalicular membrane, while mutations in BSEP and MDR3 are responsible for PFIC2 and PFIC3 diseases \[[@r23]; [@r39]; [@r179]\]. Other forms of cholestasis include primary biliary cirrhosis (PBC) and primary sclerosis cholangitis (PSC), two progressive liver disorders characterized by bile duct proliferation associated with bile flow impairment and liver damage \[[@r16]; [@r91]\].

Irrespective of the etiology of cholestasis, accumulation of toxic hydrophobic BAs in the liver is thought to play a key role in cholestasis-associated liver damage. Thus far, the use of UDCA, a polar BA that reduces the hydrophobicity and toxicity of the BA pool, is the only pharmacological intervention recognized for the management of cholestasis \[[@r137]\]. However, while endoscopy and surgery are effective therapies for most of the patients with obstructive cholestasis, therapeutic approaches based on UDCA for non-obstructive cholestasis, especially those with a genetic background, remain mostly ineffective \[[@r56]; [@r137]\]. Therapies aiming at reducing the size and hydrophobic index of the BA pool during cholestasis are still missing.

The discovery that FXR is the master regulator of BA homeostasis makes this NR a suitable pharmacological target for the management of cholestasis. Activation of FXR could reduce BA synthesis by repressing CYP7A1 and CYP8B1 expression, decrease hepatic BA uptake by downregulating the Na^+^/taurocholate cotransporting polypeptide (NTCP) and increase the expression of MDR3 and BSEP for the secretion of BAs from the liver into bile ([Figure 4](#fig4){ref-type="fig"}). The final result would be a reduced hepatic BA overload. It is noteworthy that in those forms of cholestasis that are characterized by compromised activity of BSEP and MDR3 (as in PFIC2 and PFIC3, respectively), BAs can spill over from the liver at the basolateral membrane through transporters such as OSTα/β, which also are FXR targets ([Figure 4](#fig4){ref-type="fig"}). Moreover, FXR can induce phase I and phase II reactions to make BAs more hydrophilic and ready for excretion through urine. In line with the important role that FXR plays to keep BA levels under control, FXR knock-out mice present a phenotype similar to Byler disease, a hereditary form of cholestasis with reduced FXR expression. Furthermore, four different heterozygous functional variants of FXR (-1\>g, M1V, W80R, M173T) were found in patients affected by intrahepatic cholestasis of pregnancy (ICP), a pathological condition occurring in 1/200 pregnancies in Caucasian women, that can lead to intrauterine fetal death \[[@r64]; [@r157]\]. Characterization of these variants displayed functional defects in either translational efficiency or activity in three of the four variants (-1\>g, M1V, M173T) \[[@r192]\].

The protective role of FXR activation in cholestasis has been investigated in mouse and rat models for this disease. Treatment with GW4064 reduced bile duct proliferation, inflammation and liver damage induced by bile duct ligation (BDL) and α-naphtylisothiocyanate (ANIT), the two experimental setups generally used to induce cholestasis. Moreover, both GW4064 and 6α-ECDCA were able to protect rats from ethinyl estradiol-induced cholestasis. The mechanism proposed for the protective effect of FXR observed in these studies focused only on the liver and was ascribed to the reduced expression of CYP7A1 and NTCP, and the induced expression of MRP2 and BSEP. However, since the reduced BA pool size, as a consequence of the decreased expression of CYP7A1, could play the main role in the protection against cholestasis after FXR activation, and since it was recently shown that the intestinal FXR-FGF15 pathway plays a crucial role in repressing CYP7A1 expression, the relative contribution of hepatic and intestinal FXR activation against cholestasis should be investigated by the use of tissue-specific FXR knock-out mice.

In contrast to the studies reported above, suggesting a protective role of FXR activation against cholestasis, other evidences suggest that FXR inhibition also may have a protective role in cholestasis \[[@r109]; [@r177]\]. FXR knock-out mice were shown to be protected from liver injury caused by BDL. These mice adapt to BDL by a significant increased expression of MRP4, suggesting that FXR may negatively regulate this hepatic basolateral transporter. The induction of MRP4 expression represents an important adaptive mechanism against cholestasis to protect the liver from accumulation of BAs during cholestasis, by stimulating their efflux into the systemic circulation for final renal excretion. Thus, MRP4 knock-out mice are susceptible to cholestatic-induced liver damage \[[@r114]\]. Moreover, subjects with PFIC \[[@r71]\] and mice, as well as rats, present a marked upregulation of MRP4 expression after BDL \[[@r41]; [@r114]\]. Overall, these findings imply that inhibition of hepatic FXR may represent an important adaptive mechanism observed in cholestasis.

In summary, FXR activation reduces the BA pool size, the most important determinant in cholestasis, by downregulating CYP7A1 expression *via* a synergistic mechanism that involves hepatic and intestinal FXR. However, hepatic FXR activation may also reduce the expression of basolateral transporters, such as MRP4, which are required for BA secretion into systemic circulation and consequent renal elimination. For these reasons, a selective activation of intestinal FXR would be more beneficial than a systemic activation of FXR. Through this selective activation, the total BA pool would be reduced by the FXR-FGF15/19 pathway, while the adaptive hepatic response would normally function. Another option would be the generation of drugs that would act as gene selective modulators for FXR by reducing the expression of CYP7A1, inducing the expression of BSEP, MDR3, OSTα/β and MRP4, and repressing the activity of FXR in the kidney to reduce BA uptake at this level. Finally, it is worth mentioning that the mouse models of cholestasis used so far are not completely representative of the human situation. It would be more relevant to investigate the role of FXR activation in genetic mouse models of cholestasis with the same mutations as those observed in humans (e.g., PFICs).

Cholesterol gallstone disease
-----------------------------

The correct ratio of biliary BAs, phospholipids and cholesterol is of crucial importance for maintaining cholesterol in solution in the bile and preventing the precipitation of cholesterol crystals, the first step in cholesterol gallstone formation \[[@r96]; [@r147]\]. Bile with a high BA and phospholipid versus cholesterol ratio protects from gallstone formation, while high cholesterol versus BA and phospholipid ratio predisposes to cholesterol gallstone disease (CGD). Thus, the protective role of FXR against CGD was suggested. Indeed, FXR knock-out mice are more susceptible to cholesterol gallstone formation than wild type mice, after feeding them with a lithogenic diet. This higher susceptibility is a consequence of lower BA and phospholipid versus cholesterol ratio in bile \[[@r121]\]. At the molecular level, decreased expression of *BSEP* and *Mdr2* were observed in FXR knock-out mice, while the expression of biliary cholesterol transporters, such as *ABCG5* and *ABCG8*, was unchanged. Moreover, treatment with GW4064 of C57L mice, which are susceptible to CGD when fed with a lithogenic diet, prevents gallstone formation \[[@r121]\]. Compared to vehicle-treated mice, GW4064-treated mice showed an increased expression of *BSEP* and *Mdr2* that was coupled with a higher biliary content of BAs and phospholipids and a consequent reduced cholesterol saturation index. Thus, activation of FXR is crucial for maintaining proper solubilization of cholesterol into bile, by inducing the expression of *BSEP* and *MDR3/Mdr2*, and FXR agonists may be useful for the prevention or management of CGD. However, activation of FXR inhibits BA synthesis by reducing CYP7A1 expression, resulting in a decreased BA pool size, the most important determinant of the secretory rate of BAs. This would result in less BA content in bile, increased cholesterol levels, and susceptibility to gallstone formation. Notably, in the mouse models of CGD, the use of the lithogenic diet, containing 0.5% of CA, is a must to induce gallstone formation \[[@r182]\]. The CA in the lithogenic diet increases the BA pool size and compensates for the reduced expression of CYP7A1 after GW4064 treatment. This would account for the protective effects obtained with GW4064 in this animal model of CGD despite the downregulation of CYP7A1. The situation is quite different in patients with CGD. These subjects may be treated with FXR agonists in association with hydrophilic BAs (e.g., UDCA, a prescription drug in CGD), with the synergistic effect of inducing BA and phospholipid secretion into bile while maintaining BA pool size and decreasing total BA hydrophobicity index.

Intestinal diseases
-------------------

The levels of BAs in the intestine have to be tightly regulated. Reduced intestinal BA concentration, due to bile flow obstruction, results in bacterial overgrowth and translocation across the mucosal barrier with possible systemic infection. On the other hand, an excessive level of BAs in the intestine, resulting from defects in BA reabsorption, results in chronic diarrhea, inflammatory bowel disease and promotion of intestinal tumorigenesis.

BAs have long been known to have surfactant properties responsible for keeping intestinal bacterial proliferation under control. Moreover, it has been recently shown that part of the antibacterial activity of BAs is mediated by FXR \[[@r70]\]. FXR knock-out mice exhibit hyper-proliferation of intestinal bacteria and evidence of a compromised epithelial barrier with consequent inflammation due to bacteria infiltration and recruitment of activated macrophages/neutrophils \[[@r70]; [@r118]\]. Notably, treatment of wild type mice with GW4064 was able to reverse both intestinal bacterial overgrowth and the integrity of the epithelial barrier caused by BDL \[[@r70]\]. These protective effects of FXR activation were seen in neither sham operated nor BDL FXR knock-out mice. Under physiological conditions, activation of intestinal FXR by BAs is important for controlling bacterial proliferation and maintaining the integrity of the epithelial barrier. At the transcriptional level, FXR induces the expression of genes involved in intestinal mucosa defense such as interleukin 18 (*IL18*), inducible nitric oxide synthase (*iNOS*) and carbonic anhydrase 12 (*CAR12*) ([Table 1](#table-fn1){ref-type="table"}). Moreover, induction of FGF15 by FXR could also protect the intestine. FGF15 knock-out mice present an altered intestinal morphology, suggesting that some of the functions of FXR in the intestine are mediated by FGF15 \[[@r69]\]. The relevance of this scenario for the regulation of intestinal inflammatory disorders is an active research field for several laboratories.

In humans, reduced intestinal BA reabsorption and increased fecal BA excretion contributes to chronic diarrhea occurring in different clinical contexts, including Crohn's disease, post-gastrectomy syndrome, and short bowel syndrome. In most cases, the molecular mechanisms underlying the disruption of the enterohepatic circulation are unknown. However, mutations in the *ASBT* gene is one cause for intestinal BA malabsorption in humans \[[@r133]\]. Indeed, ASBT knock-out mice recapitulate key aspects of BA malabsorption in humans \[[@r37]\]. This mouse model exhibits impaired FXR activity in both intestine and liver. Thus, FGF15 and SHP expression is reduced with consequent upregulation of CYP7A1 expression that results in a vicious cycle of increased BA production. Currently, a major drug against BA malabsorption is cholestyramine, a resin that, sequestering BAs in the intestine, protects the bowel from exposure to the increased levels of colonic BAs. However, cholestyramine is unpalatable and exhibits adverse side effects including constipation, vitamin deficiency \[[@r62]\], and hypertrigliceridemia \[[@r34]\]. In addition, by sequestering BAs in the intestine, treatment with cholestyramine could result in increased BA production by interrupting the normal feedback repression of hepatic BA synthesis. Using ASBT knock-out mice, it has been shown that GW4064-dependent FXR reactivation results in reduced BA pool size and fecal excretion as a consequence of the decreased CYP7A1 expression *via* hepatic SHP and intestinal FGF15. This finding may be of important therapeutic potential in diseases associated with BA malabsorption. Moreover, FXR agonists decrease circulating TG levels, protecting against one of the major side effects of cholestyramine and other resins. Indeed, by breaking the cycle of increased BA synthesis in BA malabsorption-related diseases, the use of synthetic FXR ligands or a hormonal therapy based on FGF19 would be beneficial for patients with either temporary or long-term interruption of enterohepatic circulation due to BA malabsorption.

Liver regeneration and tumorigenesis
------------------------------------

It has been known for a long time that BAs are able to induce hepatocyte proliferation and liver regeneration \[[@r9]\]. Conversely, blocking the enterohepatic circulation of BAs results in the inhibition of liver regeneration \[[@r188]\]. Recently, a key role for FXR in mediating BA-induced liver regeneration has been suggested. Administration of a diet containing 0.2% CA stimulated liver regeneration in partial hepatectomized mice, while a diet containing the BA sequestrant resin cholestyramine delayed liver regeneration \[[@r67]\]. In line with these observations, FXR knock-out mice presented impaired liver regeneration ability \[[@r67]\]. This data suggests a direct involvement of FXR in BA-induced liver regeneration. However, unlike BAs that have FXR-dependent and -independent activities, the use of a selective synthetic ligand for FXR such as GW4064 was unable to induce the liver regeneration process \[[@r67]\]. It is possible that a normal BA pool size can blunt the hepatic proliferative effect of FXR activation by a synthetic ligand. To investigate the hepatic proliferative effects of synthetic FXR agonists, a mouse model of partial hepatectomy with a decreased BA pool size (such as during cholestyramine treatment) should be used. The importance of BAs and FXR in hepatic proliferation is of great interest for the pathogenesis of hepatocellular carcinoma (HCC).

HCC is the primary liver tumor and is one of the most common forms of cancer in the world. The etiology of this disease mainly includes hepatitis B and C infections, alcoholic and non-alcoholic fatty liver diseases, chemicals and, to a lesser extent, genetic defects such as hematochromatosis and α-1-antitrypsin deficiency \[[@r42]; [@r150]\]. Regardless of the liver cancer etiology, irregular liver regeneration represents a general mechanism of hepatocarcinogenesis \[[@r168]; [@r189]\]. Common pathological changes in the development of liver tumors consist of inflammation and chronic liver injury, which can lead to a continuous proliferation of hepatocytes at a higher rate than normal liver cells. In contrast to the normal liver regeneration, a process where the liver resumes its normal size after an injury and stops proliferating within a short period of time, the hepatocarcinoma process consists of an uncontrolled proliferation that does not stop because of chronic injury.

Recently it has been shown that BAs can also promote liver tumorigenesis. A BA-supplied diet in a Hepatitis B Virus (HBV) transgenic mouse model was able to promote hepatic tumors, an effect also observed in Mdr2 knock-out mice \[[@r11]; [@r73]; [@r113]\]. Moreover, a CA diet has been shown to promote chemical-induced hepatocarcinogenesis \[[@r201]\]. Since FXR tightly regulates BA concentration, thereby protecting from detrimental effects of BA toxicity, a role for FXR in HCC can be supposed. In accordance with this, FXR knock-out mice, which have chronic high levels of circulating BAs, spontaneously develop HCC between 12-15 months of age \[[@r75]; [@r201]\]. These findings suggest a protective role of FXR during the life span against hepatocarcinoma development. However, whether and how FXR directly suppresses liver tumorigenesis remains to be established. It is likely that FXR acts as a metabolic oncosuppressor by keeping BA concentration under physiological levels or by reducing the toxic properties of BAs. These levels of BAs would otherwise increase to toxic levels in the absence of FXR and induce chronic hepatic injury, ultimately resulting in liver tumorigenesis. However, it is interesting to note that FXR is required for both liver regeneration and protection against hepatic tumorigenesis, suggesting an intrinsic link between these two cellular processes. This link should be exploited to find new therapies for the management of HCC.

Intestinal tumorigenesis
------------------------

The role of FXR in carcinogenesis is not restricted only to the liver. Recent studies have highlighted an oncosuppressive role for FXR in intestinal tumorigenesis \[[@r107]; [@r118]; [@r201]\]. Colorectal cancer (CRC) is a primary intestinal tumor, and is nowadays a leading cause of cancer-related death in the Western world \[[@r6]; [@r148]\]. CRC is a long multistep process that arises from a combination of genetic and environmental causes. Mutations in the tumor suppressor *adenomatous polyposis coli* (*APC*) gene are detectable in dysplastic aberrant crypt foci (ACFs), the smallest neoplastic lesion in the CRC development process, and are believed to be the *primum movens* for the initiation of the majority of sporadic and hereditary forms of CRC. These observations make APC the gatekeeper in CRC development. However, patients with APC mutations do not necessarily develop CRC; additional mutations are required in order to develop tumors and in this respect environmental factors are likely to have an important contribution \[[@r78]\]. Epidemiological studies indicate that a high fat/cholesterol diet may increase the susceptibility to CRC, while a low fat/high fiber diet can protect against CRC \[[@r198]\]. One possible mechanism by which a long term "Western-style" diet may contribute to CRC is through a chronic exposure to toxic high levels of BAs derived from excessive cholesterol catabolism. Consistent with this hypothesis, animal studies link BAs, especially secondary BAs, to CRC, and human epidemiological studies indicate that the tumor promoting activity of a "Western-style" diet is accompanied by an increase in colonic BA concentrations with higher levels in the feces \[[@r17]; [@r155]\]. Furthermore, cholecystectomy, which leads to an increased intestinal exposure to BAs, has been suggested as a predisposing factor for the development of CRC \[[@r51]; [@r82]\].

Although BAs are tumor-promoting agents, FXR is not involved in mediating their tumorigenic effects. On the contrary, FXR expression is reduced in CRC after an APC mutation, as in APC ^min/+^ mice \[[@r107]; [@r118]\], a mutant murine lineage carrying a nonsense mutation of the *APC* gene \[[@r123]\], and patients with familial adenomatous polyposis (FAP) \[[@r118]\], a hereditary form of colon cancer which just like APC ^min/+^ mice possess inactivating nonsense mutations in the *APC* gene \[[@r77]; [@r149]\]. Moreover, crossing FXR knock-out mice with APC ^min/+^ resulted in increased number and size of intestinal tumors and earlier mortality than APC ^min/+^ mice \[[@r107]; [@r118]\]. Finally, as in the APC ^min/+^ model, the lack of FXR was able to promote tumorigenesis in a chemical model of colon carcinogenesis associated with chronic colitis \[[@r107]; [@r118]; [@r146]\]. It is worth noting that, unlike liver tumorigenesis, the susceptibility of FXR knock-out mice to intestinal tumorigenesis does not relate to the elevated levels of BAs, as shown by treatment with cholestyramine, indicating that the loss of FXR, and not merely elevated BA concentrations, promotes intestinal tumors. It has been demonstrated that activated macrophages further promote WNT/β-CATENIN signaling and intestinal tumor development in APC ^min/+^ mice through the tumor necrosis factor α (TNFα) \[[@r134]\]. Moreover, it has been shown that FXR knock-out mice have a compromised intestinal architecture, with consequent bacterial translocation across the epithelial barrier and recruitment of macrophages/neutrophils \[[@r70]\]. Thus, the loss of FXR may result in increased susceptibility to CRC by further promoting WNT signaling *via* TNFα released by macrophages infiltrating into the intestinal mucosa because of altered gap-junctions \[[@r118]\].

Besides acting as an indirect oncosuppressor gene and maintaining the integrity of the intestinal mucosa barrier, activation of FXR also leads to a more direct oncosuppressing activity by blocking tumor growth in a xenograph mouse model \[[@r118]\]. Activated FXR reduces proliferation and induces apoptosis in colorectal cancer cells by increasing the mRNA levels of pro-apoptotic genes, such as *P21*, BCL-2 antagonist killer 1 (*BAK1*), *FAS*, Fas-associated death domain (*FADD*), and by decreasing the expression of anti-apoptotic genes, such as B cell lymphoma gene-2 (*BCL2*) and *TNFα*. Likewise, it has been shown that FXR also induces apoptosis in breast cancer \[[@r180]\] and in the vasculature \[[@r19]\].

In summary, it is unlikely that the intestinal tumor promoting activity of BAs is mediated by FXR, whose expression is reduced in ACFs. For this reason, FXR may be considered a new early diagnostic marker for CRC development. Moreover, the absence of FXR contributes to the increase of CRC susceptibility both directly, by inducing apoptotic events, and indirectly, by maintaining the integrity of the intestinal mucosa barrier. Thus, FXR may also be considered an intestinal oncosuppressor. Although the loss of FXR, and not merely elevated BA concentrations, increase susceptibility to intestinal tumorigenesis under a normal diet, FXR-independent tumor promoting activity of toxic high levels of BAs because of a long-term "Western-style" diet should also be considered for the pathogenesis of CRC. After mutation of the *APC* gene, FXR expression would be decreased with further promotion of intestinal tumorigenesis. In this scenario, a long-term "Western-style" diet would produce high levels of toxic BAs that will not be buffered by the detoxification activity of FXR and will be free to promote CRC *via* FXR-independent mechanisms. As a result, a high-fat diet will reduce the time window for the manifestation of CRC.

Atherosclerosis
---------------

The initial finding that FXR knock-out mice exhibit a pro-atherogenic lipid profile, having increased plasma TGs, FFA and LDL levels \[[@r172]\], suggests a protective role for FXR in atherosclerosis. However, these mice did not show features of atherosclerosis even when fed high-fat/cholesterol diets \[[@r60]; [@r209]\]. To investigate the role of FXR in atherosclerosis, FXR knock-out mice were crossed with two genetic mouse models of accelerated atherosclerosis, the ApoE- \[[@r58]; [@r60]\] and the LDLR-deficient mice \[[@r209]\] and fed with a Western diet. Female FXR^-/-^/ApoE^-/-^ mice presented less severe atherosclerosis compared to ApoE^-/-^ control mice \[[@r58]\]. In contrast, male FXR^-/-^/ApoE^-/-^ mice presented more severe atherosclerosis than ApoE^-/-^ control mice \[[@r60]\]. Indeed, compared to LDLR^-/-^ mice, male FXR^-/-^/LDLR^-/-^ exhibit decreased aortic atherosclerotic lesions \[[@r209]\]. The atheroprotective effects of FXR deficiency in female FXR^-/-^/ApoE^-/-^ mice and male FXR^-/-^/LDLR^-/-^ mice may be due to decreased LDL-cholesterol, although the mechanism resulting in this reduction remains unclear. In line with this hypothesis, female FXR^-/-^/LDLR^-/-^ mice did not display reduced atherosclerotic lesions and did not have reduced LDL-cholesterol levels. Taken together, these data suggest that the effect of the loss of FXR on atherosclerosis is dependent on the genetic background and on the sex of the animal.

In addition to the impact of FXR on cardiovascular risk factors such as dyslipidemia and hyperglycemia, FXR may also have an effect on the arterial wall. It has been demonstrated by western blot and immunohistochemical analysis that FXR is expressed in vascular smooth muscle cells (VSMCs) in human vessels and in atherosclerotic lesions \[[@r19]\]. Activation of FXR by GW4064 and 6α-ECDCA resulted in the induction of SHP and PLTP in rat smooth muscle cells (RASMCs) \[[@r94]; [@r205]\]. However, since these effects were not always confirmed with CDCA \[[@r19]; [@r205]\], it cannot be excluded that FXR ligands, other than BAs, may exist outside the enterohepatic circulation. Interestingly, 6α-ECDCA and GW4064 blunt the VSMCs inflammatory response and migration by inhibiting IL1β-induced expression of cyclooxygenase-2 (COX2) and iNOS in RASMCs, an effect achieved by decreasing NF-κB in a SHP-dependent way \[[@r94]\] ([Table 1](#table-fn1){ref-type="table"}). Furthermore, activation of FXR promotes apoptosis in RASMC cells and reduces their migration induced by platelet-derived growth factor (PDGF)-β \[[@r94]\]. Finally, FXR activation induces the expression of angiotensin type 2 receptor (*AT2R*) ([Table 1](#table-fn1){ref-type="table"}) in RASMCs, which results in inhibition of angiotensin II-mediated ERK signaling \[[@r205]\]. Notably, overexpression of AT2R and inhibition of the ERK signaling has been proposed to partially mediate the hypotensive effects of AT1R blockers \[[@r165]\] and prevent neointimal proliferation \[[@r124]\]. Although FXR activity does not impact on *AT1R* expression in RASMCs, CDCA represses angiotensinogen in a SHP-dependent fashion in hepatocytes \[[@r170]\]. Overall, FXR activation in VSMCs may have some benefit on blood pressure, vascular inflammation and neointimal proliferation.

Low expression levels of FXR were also detected in several endothelial cells such as human pulmonary artery endothelial cells (HPAEC) \[[@r152]\], rat (RPAEC) \[[@r63]\], bovine aortic endothelial cells (BAEC) \[[@r93]\] and primary human umbilical vein endothelial cells (HUVEC) \[[@r152]\]. Despite the low expression levels, activation of endothelial FXR by CDCA seems to be functional. FXR activation reduced the expression of endothelin-1 (ET-1) ([Table 1](#table-fn1){ref-type="table"}), a vasoconstrictive peptide, with possible beneficial effects against atherosclerosis \[[@r63]\]. Further beneficial effects on the vascular tone may derive from the fact that FXR directly induced the endothelial nitric oxide synthase (*eNOS*) ([Table 1](#table-fn1){ref-type="table"}) gene promoter to increase the NO production in vascular endothelial cells \[[@r93]\]. In line with these observations, reduced activity of vasoconstrictors and arterial hypotension has been reported in cirrhotic patients with high levels of circulating BAs \[[@r102]\]. On the other hand, CDCA treatment increases the expression of the adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which promote macrophage recruitment to the endothelium, a crucial process for atherosclerosis development \[[@r152]\]. However, GW4064 treatment only increases the expression of adhesion molecules at high concentrations and still to a lesser extent than CDCA. This suggests an FXR-independent activity of CDCA on ICAM-1 and VCAM-1 expression.

Taken together, the data concerning the role of FXR in the vasculature tissue should be carefully judged. The levels of FXR expression are in fact very low in this tissue making it unlikely that BAs would activate FXR *in vivo* under physiological conditions. Indeed, FXR activation in this tissue requires high doses of its specific synthetic ligand GW4064.

FXR can also affect vascular function through its hepatic activity. *In vitro* experiments on human hepatocytes displayed that FXR activation is able to induce the expression of the human *ICAM-1* promoter \[[@r152]\] ([Table 1](#table-fn1){ref-type="table"}). Moreover, mice treated with CA exhibit increased levels of ICAM-1 and VCAM-1. These findings suggest that hepatic FXR activation may be associated with promotion of the atherogenic process. On the other hand, recent data indicate that FXR activation in human hepatocytes induces the expression of kininogen \[[@r210]\] and bradykinin \[[@r108]\] ([Table 1](#table-fn1){ref-type="table"}). Kininogen is a precursor of the two-chain kinin free kininogen, which has anti-inflammation, anti-adhesion and anti-platelet aggregation activities, and bradykinin is a potent vasodilator. Therefore, induction of these two molecules may contribute to the antithrombotic activity of FXR.

In contrast, it has been shown that FXR activation induces the expression of fibrinogen, a key molecule in the coagulation pathway proposed as a cardiovascular risk factor \[[@r166]\], in an isoform-dependent manner \[[@r3]\]. Furthermore, FXR activation decreases hepatic paraoxonase 1 (PON1) expression ([Table 1](#table-fn1){ref-type="table"}), an enzyme associated with HDL that prevents LDL oxidation, with consequent anti-inflammatory atheroprotective effects \[[@r59]; [@r169]\]. It has been shown that, as for CYP7A1, FXR-mediated repression of PON1 involves the induction of FGF19 for the activation of the FGFR4-JNK pathway \[[@r59]; [@r169]\]. Thus, intestinal FXR activation may promote atherosclerosis by repressing both CYP7A1 and PON1 *via* FGF19.

Conclusions
===========

Starting from its initial cloning in 1995, the knowledge of the different functions of FXR has expanded rapidly. It is now recognized that activation of FXR not only has an impact on the homeostasis of BAs, which are the endogenous FXR ligands, but also affects lipid and glucose metabolism. Therefore, modulation of FXR activity may be exploited for the pharmacologic management of metabolic disorders related to BA and lipid/glucose metabolism, such as cholestasis, CGD, intestinal bacterial overgrowth, hepatic and intestinal tumorigenesis, dyslipidemia, hypertriglyceridemia, diabetes and atherosclerosis. From a theoretical point of view, targeting FXR may also be beneficial to treat all aspects of the metabolic syndrome, a complex cluster of cardiovascular disease risk factors including dyslipidemia, insulin-resistance, increased blood pressure, visceral obesity and hypercoagubility. However, activation of FXR may have several possible undesirable effects. For instance, activation of FXR in order to reduce TG levels in hypertriglyceridemic patients would also result in decreased HDL levels and accumulation of cholesterol in the body, as a consequence of the inhibition of BA synthesis. Also, treatment of cholestatic subjects with an FXR activator would have some beneficial effects by reducing BA synthesis, and increasing BA secretion into bile, as well as some side effects by reducing hepatic basolateral secretion of BAs. In this complex scenario, where activation of FXR integrates beneficial effects and potentially undesirable side effects, the identification of tissue-specific gene-selective FXR modulators represent an intriguing pharmacologic approach to target a specific cluster of genes avoiding detrimental side effects. Differences in the docking of the FXR ligands in the four FXR subtype receptors account for differences in corepressor dislodgement and/or coactivator recruitment in a tissue-specific manner, which could be responsible for the ability of a certain ligand to act as an agonist or antagonist for a certain gene. In the near future, more studies focusing on this aspect of FXR activation will be required to develop *ad hoc* FXR modulators. Nevertheless, we now have selective FXR agonists in the pipeline, but data obtained in human subjects in relation to the metabolic diseases are needed to verify the long list of positive or negative results observed in the different animal models. The toxicity issues have now been covered and at 14 years from the cloning of FXR, a novel nuclear receptor ligand is ready to enter the clinic.
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